MediaMedic

Real-World Eligibility in mPCa Trials: Insights from the APPLICABILITY Study Presented at EAU25

By Peter W. PENG 2025.04.06

At EAU25, Dr. Francesco Pellegrino from IRCCS San Raffaele Scientific Institute presented a crucial analysis on the generalizability of randomized trials in newly diagnosed metastatic prostate cancer (mPCa). Using the…

APPEAL Trial: Landmark International RCT Shows Ciprofloxacin Lowers Post-SWL Infection Risk

By Mourabit Halima 2025.04.06

Presented by Dr. Kari Tikkinen and team at EAU25, the APPEAL trial is the largest randomized controlled study to date evaluating the role of antimicrobial prophylaxis during shock wave lithotripsy…

BOND-003: Intravesical Cretostimogene Shows Durable Responses in High-Risk BCG-Unresponsive NMIBC

By Mourabit Halima 2025.04.06

Presented by Dr. Trinity Bivalacqua at EAU25, the BOND-003 Phase 3 trial showcases updated data on intravesical cretostimogene grenadenorepvec, an innovative oncolytic immunotherapy for patients with high-risk BCG-unresponsive non–muscle invasive…

PROQURE-I: Promising Phase I Data on [¹⁷⁷Lu]Lu-PSMA-617 in Curative Treatment of N1 Prostate Cancer Presented by Dr. Lotte G. Zuur at EAU25

By Peng Longmei 2025.04.06

At #EAU25, Dr. Lotte Zuur from the The Netherlands Cancer Institute presented the first results of the PROQURE-I study, a phase I trial evaluating the addition of [¹⁷⁷Lu]Lu-PSMA-617 to standard…

“Shared decision-making isn’t just a concept—it’s a measurable determinant of patient satisfaction.”

By Peter W. PENG 2025.04.04

At hashtag#EAU25, André Deschamps presented the results of the Europa Uomo Patient REported Shared decision making Study (EU-PRESS), shedding light on the link between perceived shared decision-making (SDM) and decision…

Dr. Sarah Psutka MD MSc presents interim results from the SunRISe-4 trial at EAU25

By Mourabit Halima 2025.04.04

At the EAU25 Congress, Dr. Sarah Psutka MD MSc shared promising data from the SunRISe-4 trial evaluating neoadjuvant TAR-200 plus cetrelimab in patients with muscle-invasive bladder cancer (MIBC) who are…

EAU25 | Dr. Dr. med. Yannic Volz Presents the PRACTICE Study: Can Prehabilitation Improve Radical Cystectomy Outcomes?

By Mourabit Halima 2025.04.03

At #EAU25, Dr. Yannic Volz (Ludwig-Maximilians-Universität München) introduced early insights from the ongoing PRACTICE trial (NCT06806059), a randomized, single-blinded study assessing the impact of structured physical activity before radical cystectomy…

EAU25 | Sustainability in Uro-Oncology: Comparing the Carbon Footprint of RC vs CRT

By Peng Longmei 2025.04.03

At #EAU25, Dr. Vera R. and colleagues from Erasmus MC presented the first study to assess the environmental impact and staff requirements of radical cystectomy (RC) versus chemoradiation (CRT) for…

EAU25 | Dr. Seth Lerner Shares First-in-Human Results on Bel-sar (AU-011) in NMIBC

By Mourabit Halima 2025.04.03

At #EAU25, Dr. Seth Lerner (Baylor College of Medicine) presented early findings from a Phase 1 study (NCT05483868) evaluating Bel-sar (AU-011)—a novel virus-like drug conjugate (VDC) for non-muscle invasive bladder…

EAU25 | Dr. Nikhil Mayor Presents NeuroSAFE PROOF Trial: Advancing Nerve-Sparing in Prostate Cancer Surgery

By Mourabit Halima 2025.04.01

At #EAU25, Dr.Nikhil Mayor (Imperial College London) presented results from the NeuroSAFE PROOF trial (NCT03317990)—the first randomized, controlled, single-blinded study comparing NeuroSAFE-guided versus standard robot-assisted radical prostatectomy (RARP) in localized…

Professor Thomas Powles: How Will ADC–Immunotherapy Combinations and ctDNA Reshape Perioperative Treatment in Bladder Cancer?

Professor Xieqiao Yan: Optimizing Post-Failure Treatment Strategies in Renal Cell Carcinoma After Targeted-Immunotherapy—Exploring New Pathways for Later-Line Therapy

Professor Ludong Qiao Interprets the IDSA Guidelines on Complicated Urinary Tract Infections: Rational Use of Cefiderocol and Novel Antibiotic Combinations

Professor Yonghong Li: Neoadjuvant Therapy for Locally Advanced Prostate Cancer—A Chinese Perspective and Clinical Balance

Research Breakthrough by Professor Qiang Lü’s Team at Jiangsu Provincial People’s Hospital: Imaging AI Enables Personalized Prognosis Prediction and Treatment Response Assessment in Bladder Cancer

Professor Guo Jianming: Greater Precision, Greater Intelligence—Three Frontier Technologies Driving Innovation in Urologic Oncology Care

Professor Xi Zheng: Apalutamide Plus ADT Enables PSA “Undetectable” Status in High-Risk Prostate Cancer Patients, Achieving a 100% 6-Month bPFS Rate

Professor Xi Zheng: Apalutamide Plus ADT Enables PSA “Undetectable” Status in High-Risk Prostate Cancer Patients, Achieving a 100% 6-Month bPFS Rate

Professor Xinan Sheng: Advancing ADC Sequencing Strategies to Overcome Drug Resistance

Advancing Precision Therapy in Urothelial Carcinoma: A Collaborative Study by Professors Xuesong Li, Qi Tang, Jianhua Zhang, and Xiaoying Li Explores a Novel Approach to HER2 Assessment

Professor Thomas Powles: How Will ADC–Immunotherapy Combinations and ctDNA Reshape Perioperative Treatment in Bladder Cancer?

Professor Xieqiao Yan: Optimizing Post-Failure Treatment Strategies in Renal Cell Carcinoma After Targeted-Immunotherapy—Exploring New Pathways for Later-Line Therapy

Real-World Eligibility in mPCa Trials: Insights from the APPLICABILITY Study Presented at EAU25

APPEAL Trial: Landmark International RCT Shows Ciprofloxacin Lowers Post-SWL Infection Risk

BOND-003: Intravesical Cretostimogene Shows Durable Responses in High-Risk BCG-Unresponsive NMIBC

PROQURE-I: Promising Phase I Data on [¹⁷⁷Lu]Lu-PSMA-617 in Curative Treatment of N1 Prostate Cancer Presented by Dr. Lotte G. Zuur at EAU25

“Shared decision-making isn’t just a concept—it’s a measurable determinant of patient satisfaction.”

Dr. Sarah Psutka MD MSc presents interim results from the SunRISe-4 trial at EAU25

EAU25 | Dr. Dr. med. Yannic Volz Presents the PRACTICE Study: Can Prehabilitation Improve Radical Cystectomy Outcomes?

EAU25 | Sustainability in Uro-Oncology: Comparing the Carbon Footprint of RC vs CRT

EAU25 | Dr. Seth Lerner Shares First-in-Human Results on Bel-sar (AU-011) in NMIBC

EAU25 | Dr. Nikhil Mayor Presents NeuroSAFE PROOF Trial: Advancing Nerve-Sparing in Prostate Cancer Surgery

Professor Thomas Powles: How Will ADC–Immunotherapy Combinations and ctDNA Reshape Perioperative Treatment in Bladder Cancer?

Professor Xieqiao Yan: Optimizing Post-Failure Treatment Strategies in Renal Cell Carcinoma After Targeted-Immunotherapy—Exploring New Pathways for Later-Line Therapy

Professor Ludong Qiao Interprets the IDSA Guidelines on Complicated Urinary Tract Infections: Rational Use of Cefiderocol and Novel Antibiotic Combinations

Professor Yonghong Li: Neoadjuvant Therapy for Locally Advanced Prostate Cancer—A Chinese Perspective and Clinical Balance

Welcome to Mediamedic 👋
It’s nice to meet you.

Welcome to Mediamedic 👋It’s nice to meet you.

Welcome to Mediamedic 👋
It’s nice to meet you.